Wellspring Financial Advisors LLC Makes New Investment in Cencora, Inc. $COR

Wellspring Financial Advisors LLC purchased a new position in Cencora, Inc. (NYSE:COR) during the 4th quarter, HoldingsChannel reports. The firm purchased 2,238 shares of the company’s stock, valued at approximately $756,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Oakworth Capital Inc. bought a new stake in Cencora in the fourth quarter worth about $26,000. Elyxium Wealth LLC bought a new stake in Cencora in the fourth quarter worth about $27,000. Archer Investment Corp raised its position in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares in the last quarter. IAG Wealth Partners LLC bought a new stake in Cencora in the third quarter worth about $30,000. Finally, Caitlin John LLC bought a new stake in Cencora in the third quarter worth about $31,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Up 0.7%

Shares of Cencora stock opened at $281.48 on Thursday. The company’s fifty day simple moving average is $290.59 and its 200-day simple moving average is $328.55. The company has a market cap of $54.76 billion, a price-to-earnings ratio of 21.59, a PEG ratio of 1.51 and a beta of 0.59. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts expect that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora declared that its board has initiated a stock repurchase program on Thursday, May 21st that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 3.9% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is 18.40%.

Analyst Upgrades and Downgrades

Several brokerages have commented on COR. Barclays dropped their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research report on Wednesday. Morgan Stanley set a $342.00 price objective on Cencora in a report on Friday, May 8th. Robert W. Baird cut their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Evercore set a $360.00 price objective on Cencora in a report on Wednesday, April 8th. Finally, Wells Fargo & Company cut their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th. Twelve analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and an average target price of $374.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.